ROPINIROLE HYDROCHLORIDE

Clinical safety rating: safe

Animal studies have demonstrated safety

How it works

Ropinirole is a non-ergoline dopamine agonist with high affinity for D2 and D3 dopamine receptors, particularly D3. It stimulates postsynaptic dopamine receptors in the striatum, compensating for dopamine deficiency in Parkinson's disease and modulating dopaminergic pathways in restless legs syndrome.

What the body does with it

Metabolism	Primarily metabolized by CYP1A2 (major), with minor contributions from CYP3A4. Metabolites are inactive. Saturable first-pass metabolism occurs.
Excretion	Renal: 88% (primarily as metabolites, <10% unchanged). Fecal: <5%.
Half-life	Terminal elimination half-life: 5-6 hours in young healthy adults; 6-8 hours in elderly. Clinically, steady-state achieved within 2 days.
Protein binding	40% bound to plasma proteins (primarily albumin).
Volume of Distribution	7.5 L/kg (approximate) indicating extensive extravascular distribution.
Bioavailability	Oral: 50-55% (due to first-pass metabolism).
Onset of Action	Oral immediate-release: 1-2 hours. Oral extended-release: 4-6 hours.
Duration of Action	Immediate-release: 8-12 hours (dose-dependent). Extended-release: 24 hours with once-daily dosing.

Classification & Brands

Dosing & administration

Initial: 0.25 mg orally three times daily; titrate weekly by increments of 0.25 mg three times daily up to 1 mg three times daily, then 0.5 mg three times daily up to 3 mg three times daily; maximum 8 mg three times daily (24 mg/day).

Dosage form	TABLET
Renal impairment	No dose adjustment required for mild to moderate renal impairment (CrCl 30-80 mL/min). For severe impairment (CrCl <30 mL/min) or hemodialysis, initial dose should be increased cautiously; maximum dose may need to be reduced. Specific GFR-based guidelines not established.
Liver impairment	Child-Pugh Class A or B: No adjustment recommended. Child-Pugh Class C: Not studied; use with caution and consider dose reduction.
Pediatric use	Not approved for pediatric use; safety and efficacy not established.
Geriatric use	Initiate with lower doses (0.25 mg three times daily) and titrate cautiously due to increased risk of adverse effects (e.g., hallucinations, orthostatic hypotension). Monitor renal function as age-related decline may affect clearance.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

CYP1A2 inhibitors may increase levels Can cause somnolence and impulse control disorders.

Breastfeeding	Excretion into breast milk unknown; M/P ratio not established. Due to potential for somnolence and hypotonia in infants, breastfeeding is not recommended during therapy.
Teratogenic Risk	Pregnancy category C. First trimester: insufficient data; animal studies show fetal harm (skeletal abnormalities, decreased fetal weight) at maternally toxic doses. Second/third trimester: no adequate human studies; risk of extrapyramidal effects in neonates if used near term.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Common Effects	restless legs syndrome
Serious Effects

Absolute Contraindications

["Hypersensitivity to ropinirole or any component of the formulation"]

Clinical Precautions

Precautions

["May cause orthostatic hypotension and syncope, especially during dose titration","Risk of dopamine dysregulation syndrome (compulsive behaviors such as gambling, hypersexuality, binge eating)","Somnolence and sudden sleep onset during daily activities","Impulse control disorders","Hallucinations and psychotic-like behavior","Fibrotic complications (pleural, pericardial, retroperitoneal fibrosis) – rare risk similar to ergot derivatives","Augmentation and rebound in restless legs syndrome with long-term use","Neuroleptic malignant syndrome (NMS) upon rapid dose reduction or withdrawal","May exacerbate dyskinesias in Parkinson's disease","Avoid abrupt discontinuation to prevent withdrawal symptoms"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…